Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression

Histologic variant (HV) subtypes of bladder cancer are clinically aggressive tumors that are more resistant to standard therapy compared to conventional urothelial carcinoma (UC). Little is known about the transcriptional programs that account for their biological differences. Here we show using single cell analysis that HVs harbor a tumor cell state characterized by expression of MUC16 (CA125), MUC4, and KRT24. This cell state is enriched in metastases, predicted to be highly resistant to chemotherapy, and linked with poor survival. We also find enriched expression of TM4SF1, a transmembrane protein, in HV tumor cells. Chimeric antigen receptor (CAR) T cells engineered against TM4SF1 protein demonstrated in vitro and in vivo activity against bladder cancer cell lines in a TM4SF1 expression-dependent manner, highlighting its potential as a therapeutic target.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2025-06-17
DOI
https://doi.org/10.1038/s41467-025-59888-8
Citations
6
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
12.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression

Timothy Gilpatrick, Maxwell V. Meng, Hanbing Song, Corynn Kasap et al.
6 citations
Nature Communications
Bladder and Urothelial Cancer Treatments
12.04
article

Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression

Timothy Gilpatrick, Maxwell V. Meng, Hanbing Song, Corynn Kasap, Jonathan Chou, Keliana Hui, Paul Allegakoen, Chien‐Kuang Cornelia Ding, Kevin Chang, Bradley A. Stohr, Heiko Yang, Sima P. Porten, Arun P. Wiita, Vipul Kumar, Franklin W. Huang, Kevin Lu, Elizabeth Yip, J. Gayle, Julia H Pham
article en
6 citations

Abstract

Histologic variant (HV) subtypes of bladder cancer are clinically aggressive tumors that are more resistant to standard therapy compared to conventional urothelial carcinoma (UC). Little is known about the transcriptional programs that account for their biological differences. Here we show using single cell analysis that HVs harbor a tumor cell state characterized by expression of MUC16 (CA125), MUC4, and KRT24. This cell state is enriched in metastases, predicted to be highly resistant to chemotherapy, and linked with poor survival. We also find enriched expression of TM4SF1, a transmembrane protein, in HV tumor cells. Chimeric antigen receptor (CAR) T cells engineered against TM4SF1 protein demonstrated in vitro and in vivo activity against bladder cancer cell lines in a TM4SF1 expression-dependent manner, highlighting its potential as a therapeutic target.

Nature CommunicationsVol. 16(1)
San Francisco VA Medical Center (US), University of California, Santa Barbara (US), University of California, San Francisco (US), Chan Zuckerberg Initiative (United States) (US), University of Colorado Anschutz Medical Campus (US)
California Urology Foundation, Urology Foundation, University of California, San Francisco, Department of Medicine, University of California, San Francisco
No poverty
Openalex Percentile: Top 1%
Bladder and Urothelial Cancer Treatments
12.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.